Aristotle University Of Thessaloniki (AUTH)
Συσχέτιση της μη αλκοολικής στεατοηπατίτιδας με την αρτηριακή σκληρία σε ασθενείς με μεταβολικό σύνδρομο πριν και μετά υπολιπιδαιμική αγωγή
Abstract
dc:descriptionAt present there is no effective treatment for non-alcoholic fatty liver disease (NAFLD) or its advanced form, non-alcoholic steatohepatitis (NASH). The aim of the study was to investigate the effect of rosuvastatin monotherapy on NASH and pulse wave velocity (PWV). This prospective study included 20 biopsy proven patients with NASH, MetS and dyslipidaemia. Patients received lifestyle advice and were treated for 12 months with rosuvastatin (10 mg/day) monotherapy. A repeat biopsy, repeat ultrasonography of the liver and repeat PWV measurements were performed at the end of the study in all patients. Liver enzymes, fasting plasma glucose, serum uric acid , and lipid profile were assessed every 3 months. The primary endpoint was resolution of NASH and improvement in PWV values. The repeat liver biopsy and ultrasonography showed complete resolution of NASH in 19 patients in combination with concomitant reduction of PWV values, while the 20th, which had no improvement but no deterioration either, developed arterial hypertension and substantial rise in triglyceride levels during the study, probably due to changes in lifestyle including alcohol abuse. Serum alanine transaminase, aspartate transaminase, γ-glutamyltranspeptidase, and alkaline phosphatase activities were normalised by the 6th treatment month. Fasting plasma glucose and glycated haemoglobin were significantly reduced. Lipid values were normalised by the 3rd treatment month. No patient had MetS by the 9th treatment month. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed solely to rosuvastatin treatment. A limitation of the study is the absence of a control group. These findings suggest that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve MetS within 12 months in combination with arterial stiffness improvement. These effects and the reduction of fasting plasma glucose and SUA levels may reduce the risk of vascular and liver morbidity and mortality in NASH patients. These findings need confirmation in larger studies.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kargiotis, Konstantinos
- Καργιώτης, Κωνσταντίνος
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37868